Q Bio has raised $27 million in strategic funding to accelerate the company’s plans to bring its Mark I full-body MRI scanner to market.
The Mark I uses Q Bio’s advances in tensor field mapping to offer full-body scans with immediate access to data across more than 3,000 anatomical measurements, Q Bio said. Its design aims to gather quantitative anatomical data from a single scan, powering digital twins and large biological models at population scale. It requires no special rooms, no radiation, no breath holds, and is designed with an open structure for patient comfort. Q Bio said that scans from the Mark I are completed in 10 minutes and can be deployed in a primary care clinic.
Participants in the funding round include new investor Telus Global Ventures alongside existing investors, including Khosla Ventures, Andreessen Horowitz, Founders Fund, and Kaiser Foundation Hospitals.